Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


Purpose:

RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Combining interleukin-7 with vaccine therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 when given with vaccine therapy in treating patients with metastatic melanoma.


Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose of interleukin-7 (IL-7) when administered with melanoma peptide vaccine emulsified in Montanide ISA-51 in patients with metastatic melanoma. - Determine the safety of this regimen in these patients. Secondary - Determine the biological effects of this regimen on T-cell function and phenotype at various doses and at the optimal biological dose in these patients. - Determine the pharmacokinetic and pharmacodynamic characteristics of IL-7 in patients treated with this regimen. - Determine the antitumor effects of IL-7, in terms of a dose-escalation strategy, in these patients. OUTLINE: This is a dose-escalation study of interleukin-7 (IL-7). Patients receive IL-7 subcutaneously (SC) on days 0, 3, 6, 9, 12, 15, 18, and 21. Patients also receive melanoma peptide vaccine comprising gp100 antigen and MART-1 antigen emulsified in Montanide ISA-51 SC on days 0, 7, 14, and 21 in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of IL-7 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 13 patients are treated at that dose level. Patients are followed at 1, 2, and 5 weeks, at 3 and 6 months, and then at 1 year. PROJECTED ACCRUAL: A total of 3-37 patients will be accrued for this study within 1-12.3 months.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed melanoma - Metastatic disease - Measurable or evaluable disease - Disease progression during or after prior interleukin-2 (IL-2) OR ineligible to receive high-dose IL-2* OR has disease burden for which IL-2 is not indicated* NOTE: *If patient did not receive prior IL-2, must have progressed after prior standard first-line therapy (e.g., metastasectomy for single lesions or dacarbazine) - HLA-A*0201-positive disease PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 3 months Hematopoietic - Absolute neutrophil count > 1,000/mm^3* - Absolute lymphocyte count ≥ 200/mm^3* - Platelet count > 100,000/mm^3 - No proliferative hematologic disease NOTE: *For 2 consecutive readings performed on 2 different days Hepatic - AST and ALT < 3 times upper limit of normal (ULN) - PT/PTT ≤ 1.5 times ULN - Hepatitis B negative - Positive hepatitis B serology indicative of prior immunization (i.e., positive for antibody against hepatitis B surface antigen AND negative for antibody against hepatitis B core antigen) allowed - Hepatitis C negative Renal - Creatinine ≤ 1.4 mg/dL Cardiovascular - Ejection fraction > 45% by MUGA for patients ≥ 50 years of age OR with a history of cardiac disease - No resting blood pressure > 140/90 mm Hg with standard antihypertensive therapy Pulmonary - DLCO/VA and FEV_1 > 50% of predicted on pulmonary function test for smokers OR for patients with clinical evidence of compromised pulmonary function - No history of severe asthma Immunologic - HIV negative - No history of autoimmune disease - No splenomegaly Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No other medical or psychiatric disease that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - More than 4 weeks since prior cytokines - No prior allogeneic hematopoietic stem cell transplantation - No concurrent growth factors - No concurrent monoclonal antibodies - No other concurrent immunotherapy - No other concurrent cytokines - No other concurrent biologic agents Chemotherapy - See Disease Characteristics - No prior intensive myeloablative chemotherapy - No concurrent chemotherapy Endocrine therapy - More than 2 weeks since prior systemic corticosteroids for more than 72 hours in duration - No concurrent systemic steroids Radiotherapy - Not specified Surgery - See Disease Characteristics - No prior splenectomy - No prior solid organ transplantation Other - More than 4 weeks since prior cytotoxic therapy - No other concurrent cytotoxic therapy - No concurrent chronic anticoagulation therapy (e.g., high-dose warfarin, heparin, or aspirin) - Concurrent low-dose warfarin (1-2 mg) allowed - No concurrent chronic medication for asthma - No concurrent immunosuppressive therapy


NCT ID:

NCT00091338


Primary Contact:

Principal Investigator
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20892
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.